bioRxiv · 10.1101/604777
Novel lead compounds that target the ribosomal peptidyl transferase center
Abstract
M. tuberculosis (Mtb) is a pathogenic bacterium that causes tuberculosis, which kills more than 1.5 million people worldwide every year. Strains resistant to available antibiotics pose a significant healthcare problem. The enormous complexity of the ribosome poses a barrier for drug discovery. We have overcome this in a tractable way by using an RNA segment that represents the peptidyl transferase center as a target. By using a novel combination of NMR transverse relaxation times (T2) and computational chemistry approaches, we have obtained improved inhibitors of the Mtb ribosomal PTC. Two phenylthiazole derivatives were predicted by machine learning models as effective inhibitors, and this was confirmed by their IC50 values, which were significantly improved over standard antibiotic drugs.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Tam, B., Cohen, S., Sherf, D., Eisdorfer, S. A., Perez, M., Soffer, A., Vilenchik, D., Wagner, G., Akabayov, B.. 2019-04-10. Novel lead compounds that target the ribosomal peptidyl transferase center. https://doi.org/10.1101/604777
Cite the original work for its findings. Save a collection to share your selection of sources.